Effects of a dopamine agonist on the pharmacodynamics of levodopa in parkinson disease

Archives of Neurology

Volumn 67, Issue 1, 2010, Pages 27-32

  Brodsky, Matthew A ^a   Park, Byung S ^b   Nutt, John G ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA; PLACEBO; PRAMIPEXOLE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; AMBULATORY CARE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSKINESIA; HUMAN; IDIOPATHIC DISEASE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPONSE TIME; WALKING;

ADULT; AGED; AGED, 80 AND OVER; BENZOTHIAZOLES; BRAIN; CROSS-OVER STUDIES; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LEVODOPA; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PARKINSON DISEASE; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 74949130888     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2009.287     Document Type: Article

References (18)

1. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA. 2000;284(15):1931-1938.
2. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342(20): 1484-1491.
3. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology. 1997;49(1):162-168.
4. Möller JC, Oertel WH, Koster J, Pezzoli G, Provinciali L. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial. Mov Disord. 2005;20(5):602-610.
5. Pinter MM, Pogarell O, Oertel WH. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study. J Neurol Neurosurg Psychiatry. 1999;66(4):436-441.
6. Hauser RA, Deckers F, Lehert P. Parkinson's disease home diary: further validation and implications for clinical trials. Mov Disord. 2004;19(12):1409-1413.
7. Nutt JG, Woodward WR, Carter JH, Gancher ST. Effect of long-term therapy on the pharmacodynamics of levodopa: relation to on-off phenomenon. Arch Neurol. 1992;49(11):1123-1130.
8. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinic-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181-184.
9. Homann CN, Suppan K, Wenzel K, et al. The bradykinesia akinesia incoordination test (BRAIN test), an objective and user-friendly means to evaluate patients with parkinsonism. Mov Disord. 2000;15(4):641-647.
10. van Hilten JJ, Wagemans EAH, Ghafoerkhan SF, van Laar T. Movement characteristics in Parkinson's disease: determination of dopaminergic responsiveness and threshold. Clin Neuropharmacol. 1997;20(5):402-408.
11. Boraud T, Tison F, Gross C. Quantification of motor slowness in Parkinson's disease: correlations between the tapping test and single joint ballistic movement parameters. Parkinsonism Relat Disord. 1997;3(1):47-50.
12. Nutt JG, Woodward WR, Anderson JL. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism. Ann Neurol. 1985;18(5):537-543.
13. Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL. The "on-off" phenomenon in Parkinson's disease: relation to levodopa absorption and transport. N Engl J Med. 1984;310(8):483-488.
14. Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson disease: a randomized dose-ranging study. JAMA. 1997;278(2):125-130.
15. Nutt JG, Gancher ST, Woodward WR. Does an inhibitory action of levodopa contribute to motor fluctuations? Neurology. 1988;38(10):1553-1557.
16. Bonnet AM, Serre I, Marconi R, Agid Y, Dubois B. A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine. Mov Disord. 1995;10(5):668-671.
17. Zarrindast MR, Eliassi A. Differential effects of dopamine agonists on locomotion in intact and reserpine-treated mice. Gen Pharmacol. 1991;22(6):1027-1031.
18. Maj J, Rogoz Z, Skuza G, Kołodziejczyk K. The behavioural effects of pramipexole, a novel dopamine receptor agonist. Eur J Pharmacol. 1997;324(1): 31-37.